Business Description
Climb Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US28658R1068
Description
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3333.64 | |||||
| Equity-to-Asset | 0.99 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.4 | |||||
| 3-Year FCF Growth Rate | 14.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.9 | |||||
| 9-Day RSI | 20.49 | |||||
| 14-Day RSI | 23.81 | |||||
| 6-1 Month Momentum % | -59.71 | |||||
| 12-1 Month Momentum % | 16.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 57.73 | |||||
| Quick Ratio | 57.73 | |||||
| Cash Ratio | 56.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.4 | |||||
| Shareholder Yield % | 0.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.19 | |||||
| ROA % | -44.27 | |||||
| ROIC % | -1207.37 | |||||
| ROC (Joel Greenblatt) % | -31552.57 | |||||
| ROCE % | -49.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.61 | |||||
| Price-to-Tangible-Book | 0.61 | |||||
| EV-to-EBIT | 0.84 | |||||
| EV-to-EBITDA | 0.84 | |||||
| EV-to-FCF | 5.84 | |||||
| Price-to-Net-Current-Asset-Value | 0.8 | |||||
| Price-to-Net-Cash | 0.82 | |||||
| Earnings Yield (Greenblatt) % | 119.05 | |||||
| FCF Yield % | -8.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLYM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Climb Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.13 | ||
| Beta | -0.64 | ||
| Volatility % | 170.74 | ||
| 14-Day RSI | 23.81 | ||
| 14-Day ATR ($) | 0.233129 | ||
| 20-Day SMA ($) | 2.71425 | ||
| 12-1 Month Momentum % | 16.41 | ||
| 52-Week Range ($) | 1.86 - 11.55 | ||
| Shares Outstanding (Mil) | 67.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Climb Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Climb Bio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Climb Bio Inc Frequently Asked Questions
What is Climb Bio Inc(CLYM)'s stock price today?
The current price of CLYM is $2.21. The 52 week high of CLYM is $11.55 and 52 week low is $1.86.
When is next earnings date of Climb Bio Inc(CLYM)?
The next earnings date of Climb Bio Inc(CLYM) is 2025-02-12 Est..
Does Climb Bio Inc(CLYM) pay dividends? If so, how much?
Climb Bio Inc(CLYM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers